指南与共识自身炎症与 IgG4 相关病

美国风湿病学会关于VEXAS诊断与管理的指导声明:由国际VEXAS工作组专家小组制定

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.
指南 / 共识 · Arthritis Rheumatol · 2025-08-11

VEXAS是一种与UBA1基因体细胞突变相关的罕见遗传病,兼具炎症与血液学表现,致残致死率增高。鉴于疾病表现异质且研究有限,国际多学科专家组通过正式会议与投票流程制定首部国际共识临床指导,涵盖VEXAS临床特征、UBA1筛查方法、VEXAS背景下骨髓增生异常综合征(MDS)的诊断以及预后与管理。

要点

  • VEXAS由UBA1基因体细胞突变引起,表现为炎症与血液学异常组合。
  • 专家组就VEXAS临床特征、UBA1筛查方法、MDS诊断及预后管理形成共识指导。
  • 该共识为临床医生理解VEXAS及其管理提供首部国际正式指导资源。

核心结论

  • 该工作标记为首个针对VEXAS的正式国际共识指导,旨在作为临床医生了解该病及其管理的资源。

研究设计与样本

  • 由国际多学科VEXAS专家小组通过正式化会议与投票流程制定共识临床指导考虑。

主要发现

  • 共识考虑就以下关键主题提供实用建议:VEXAS的临床特征、UBA1筛查方法、VEXAS患者中骨髓增生异常综合征(MDS)的诊断、预后与管理。

关键数值与推荐

  • 共识指导旨在说明哪些患者应检测、如何检测VEXAS、如何在VEXAS背景下处理MDS以及管理考虑。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vacuoles E1 enzyme X-linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. METHODS: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. RESULTS: Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. CONCLUSION: This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mekinian A, Georgin-Lavialle S, Ferrada MA, et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel. Arthritis Rheumatol. 2025. PMID: 40787890. doi:10.1002/art.43287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。